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Abstract
Background: Selection of early stage non-small cell lung cancer patients with a high risk of recurrence is warranted in 
order to select patients who will benefit from adjuvant treatment strategies. We evaluated the prognostic value of 
integrin expression profiles in a retrospective study on frozen primary tumors of 68 patients with early stage non-small 
cell lung cancer.
Methods: A retrospective study was performed on frozen primary tumors of 68 early stage non-small cell lung cancer 
patients with a follow up of at least 10 years. From all tumor tissues, RNA was isolated and reverse transcribed into 
cDNA. qPCR was used to generate mRNA expression profiles including integrins alpha1, 2, 3, 4, 5, 6, 7, 11, and V as well 
as integrins beta1, 3, 4, 5, 6, and 8.
Results: The expression levels of integrins alpha5, beta1 and beta3 predicted overall survival and disease free survival 
in early stage NSCLC patients. There was no association between integrin expression and lymph node metastases. 
Comparison between the histological subtypes revealed a distinct integrin signature for squamous cell carcinoma 
while the profiles of adenocarcinoma and large cell carcinoma were largely the same.
Conclusion: Integrin expression in NSCLC is important for the development and behavior of the tumor and influences 
the survival of the patient. Determining the integrin expression profile might serve as a tool in predicting the prognosis 
of individual patients.
Introduction
Lung cancer is the most common cause of cancer related
death in Europe, accounting for one-fifth of the total
number of cancer deaths[1]. The prognosis of patients
with non-small cell lung cancer (NSCLC), which consti-
tutes 80% of all lung cancers, is poor, even in patients
with early stage disease[2]. The five year survival rate of
patients with resected NSCLC is between 50-60%, and
50-60% of patients will have disease recurrence within 2
years[3]. Recently, it has been shown that adjuvant che-
motherapy improves overall and disease-free survival in
patients with resected stage stage II-IIIa NSCLC, but not
all patients benefit[3]. Thus, selection of patients with
high risk of recurrence is warranted.
An important predictor of poor prognosis in patients
with NSCLC is early distant metastasis[2]. When cancer
cells become metastatic, they develop altered affinity and
avidity for the extracellular matrix (ECM). This pheno-
typic change is partly due to alterations in the expression
of cell-surface molecules known as integrins. Integrins
are a family of glycoproteins that form heterodimeric
receptors for ECM molecules such as laminin, fibronectin
and collagen[4]. Each integrin generally consists of a non-
covalently linked α- and β-subunit, with each subunit
having a large extracellular domain, a single membrane-
spanning domain, and a short, non-catalytic cytoplasmic
tail[4]. Besides their role in mediating interactions of cells
with the extracellular matrix, integrins also participate in
signal transduction and influence different cell functions
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such as migration, differentiation, proliferation and apop-
tosis[5,6]. Consequently, integrins are involved in differ-
ent steps of tumor progression[7].
The expression of integrins has been suggested to play a
role in predicting the clinical course and prognosis of
NSCLC[8-13]. For example, increased expression of inte-
grin alpha5 and beta1 has been associated with lymph
node metastasis. Increased expression of integrin alpha5
may also be a predictor of a poor 5-year survival
rate[8,11]. However, integrin expression in NSCLC
remains ambiguous[13]. The expression of integrin
alpha3 has been found increased as well as decreased in
adenocarcinoma of the lung and has been suggested a
factor of poor prognosis[9,10]. Loss of integrin alphaV
expression has been linked to recurrence in patients with
lymph node-negative lung carcinoma, but high expres-
sion of this integrin has also been associated with poor
patient outcome[12,14]. Apart from these conflicting
findings, most studies only assess the expression of a sin-
gle or a few integrins and information on the relation
between the overall integrin expression profile and dis-
ease progression is scarce. To gain better insight in the
prognostic value of integrin expression in NSCLC, we
performed extensive integrin expression profiling in pri-
mary tumors of patients with resected early stage
NSCLC.
Patients and Methods
Patients
Primary tumor tissue was obtained from patients with
NSCLC who underwent a surgical resection between
1995 and 1999. Exclusion criteria were 1) previous other
malignancy, or 2) development of an unrelated malig-
nancy during a follow-up of at least 4 years. Both frozen
tumor tissues (-80°C) and formalin fixed paraffin embed-
ded tissues were obtained from the Maastricht Pathology
Tissue Collection. Frozen tissue sections (8 μm) were
stained with hematoxilin/eosin and re-evaluated by an
experienced pathologist (R-J v S). Only tissues with a
tumor area >50% were included for further investigations.
The study complies with the recommendations guiding
physicians in biomedical research involving human sub-
jects as laid down in the Declaration of Helsinki.
RNA isolation and cDNA synthesis
Total RNA was isolated from ten × 10 μm thick frozen tis-
sue sections using RNeasy RNA isolation kit (Qiagen)
according to the manufacturer's instructions. Possible
genomic DNA contaminations were removed by on col-
umn DNAse treatment with the RNase-free DNAse set
(Qiagen). cDNA synthesis was performed with the iScript
cDNA Synthesis Kit (BioRad) using 100 ng total RNA as
input.
Primers design
Primers were designed as described previously[15]. Prim-
ers were targeted against integrin alpha1 (INTa1), alpha2
(INTa2), alpha3 (INTa3), alpha4 (INTa4), alpha5 (INTa5),
alpha6 (INTa6), alpha7 (INTa7), alpha11 (INTa11),
alphaV (INTaV), beta1 (INTb1), beta3 (INTb3), beta4
(INTb4), beta5 (INTb5), beta6 (INTb6), beta8 (INTb8),
beta-actin (bACT), cyclophilin A (cycloA), beta-2-micro-
globulin (b2MG) and hypoxanthine-guanine phosphori-
bosyltransferase 1 (HPRT1). The primers specifically
target human sequences and were synthesized by Euro-
gentec.
Real-time qPCR
Real-time qPCR was performed on the iQ5 Multicolor
Real-Time PCR Detection System device (BioRad) and
the CFX96 (BioRad) using the iQ SYBR Green PCR mas-
ter mix (BioRad). The PCR reaction was performed in a
25 μL volume containing 30 ng cDNA, 12.5 μL 2× iQ
SYBR Green PCR master mix and 1 μL of primer mix (10
μM forward primer, 10 μM reverse primer). The PCR
profile was as follows: 10 minutes at 95°C, followed by 40
cycles of 15 seconds at 95°C and 30 seconds at 60°C. Sub-
sequently, a melting curve analysis was performed which
consisted of 70 cycles of 10 seconds with a temperature
increment of 0.5°C/cycle starting from 60°C. The
obtained Ct value of each gene of interest was normalized
to the Ct of the reference genes as follows: Ctnorm = Ctgoi -
Ctref with Ctref = (CtbACT × CtCycloA × Ctb2MG × CtHPRT)(1/4)
with norm = normalized, goi = gene of interest, and ref = ref-
erence gene.
Statistical analysis
The real time RT-PCR data are given as mean values ±
SEM. Survival comparisons were done using Kaplan-
Meier survival estimates and the log-rank test for deter-
mining survival differences. Median integrin expression
level was used as cut of value to divide the groups in high
and low expression. The Student's t test was used to com-
pare expression between the different histological groups.
Statistical computations were performed in SPSS 12.0.1.
and p-values < 0.05 were considered statistically signifi-
cant.
Results
Patient characteristics
Of the initial 71 patients included in this study, one was
excluded because of poor quality of the tissue and two
were excluded because of incomplete follow-up. The
average age of the remaining 68 patients was 69.1 years
(range 44.5 - 90.2). None of the patients received adjuvant
chemotherapy. The median follow-up was 93 months
(95% CI 85 - 101 months) and the median overall survival
was 27.3 months (range 2.3 - 126.7). During the follow-upDingemans et al. Molecular Cancer 2010, 9:152
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period, 43 patients (67%) had disease recurrence and the
2 year survival rate was 51%. The patients characteristics
are summarized in Table 1.
Integrin primer design and validation
A subset of 15 integrins was selected covering the binding
to different ligands, i.e. collagen, fibronectin, laminin, vit-
ronectin, and von Willebrand's factor. Primers were
designed to specifically target only human integrins as
described previously[15] (Table 2). Specific detection of a
particular integrin was confirmed by agarose gel electro-
phoresis (Figure 1A). To ensure equal PCR efficiency for
all primer sets, dilution series of the PCR product encom-
passing both primer binding sites was used as template
for real-time qPCR analysis. Plotting the Ct value against
the logarithm of dilution factor should theoretically result
in a linear curve with a slope of approximately -3.32 (=-
2log(10)). In addition, this approach allowed us to deter-
mine the upper Ct limit, i.e. the highest Ct value that still
was in the linear range. All primer sets showed an compa-
rable amplification efficiency over a broad range of con-
centrations (Figure 1B and Table 3). These data
confirmed that all primers have a comparable perfor-
mance in qPCR.
Integrin alpha5, beta1, and beta3 expression are 
prognostic factors for overall survival in early stage NSCLC 
patients
Next, the integrin expression profile of all the NSCLC tis-
sues from the total patient group was determined. The
expression levels of the different integrins varied consid-
erably with integrin alphaV, beta1, beta4 and beta5 dis-
playing the highest expression levels (Figure 1C). The
expression of integrin alpha1, alpha2, alpha3, and alpha5
was lower and hardly any integrin alpha4 and integrin
beta3 was detected. In addition, while most integrins
were expressed at detectable levels, i.e. below the upper
Ct limit, integrin alpha1 and integrin beta3 were only
detectable in respectively 42% and 33% of the patients.
Next, we analyzed the overall survival in patients grouped
according to the expression level of a specific integrin.
This revealed that patients which express integrin alpha3,
alpha5, beta1, or beta3 above median levels have a signifi-
cant shorter overall survival compared to patients whose
integrin expression levels are below the median (Figure 2
and Table 4).
Integrin expression as marker for lymph node metastasis 
and recurrence
Of the 68 patients included in this study, 19 patients
(28%) had positive lymph nodes (N1) at the time of diag-
nosis. There was no difference in the integrin expression
levels between patients with N1 disease and N0 disease
(data not shown). Apparently, integrin expression in the
primary tumor does not predict the presence of lymph
node metastasis. However, similar as for the overall sur-
vival, Kaplan Meier analysis indicated that elevated
expression of integrin alpha5, beta1, or beta3 was associ-
ated with shorter disease free survival DFS (Figure 3 and
Table 5).
Integrin expression in different histological subtypes of 
NSCLC
Finally, the integrin expression of the 3 main histological
subtypes included in this study, i.e. squamous cell carci-
noma, adenocarcinoma, and large cell carcinoma, was
compared. Integrin alpha2 and beta4 were significantly
higher expressed in squamous cell carcinomas as com-
pared to both adenocarcinoma and large cell carcinoma
(Figure 4A). The same trend was observed for integrin
alpha5 and integrin beta5, albeit only statistically signifi-
cant for squamous carcinoma vs. adenocarcinoma. The
latter also appeared to be characterized by increased
expression of integrin alpha3 and beta1 as compared to
squamous carcinoma. A summary of the fold-differences
in integrin expression between the different histological
subtypes is given in Table 6. Correlation analysis indi-
cated that the integrin expression profile of squamous cell
carcinomas appeared to differ most from both adenocar-
Table 1: Characteristics of included NSCLC patients.
Total number of patients 68
Median age in years (range) 69.1 (44.5 - 90.2)
Sex
Male 51 (75%)
Female 17 (25%)
Histology
Adenocarcinoma 24 (35%)
Squamous cell carcinoma 33 (49%)
Large cell carcinoma 10 (15%)
Pleiomorph carcinoma 1 (1%)
Stage (TNM)
Stage IA 6 (9%)
Stage IB 34 (50%)
Stage IIA 6 (9%)
Stage IIB 18 (26%)
Stage IIIA 4 (6%)
Smoking status
Never 2 (3%)
Former 42 (62%)
Current 19 (28%)
Unknown 5 (7%)
Median OS in months (range) 27.3 (1.7-126.7)
Median DFS in months (range) 16.6 (1.6 - 125.2)Dingemans et al. Molecular Cancer 2010, 9:152
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cinoma and large cell carcinoma. Indeed, the expression
profiles of the latter two showed the strongest correlation
with a correlation coefficient of 0.940 (p < 0.0001) (Figure
4B). Since the adenocarcinoma and large cell carcinoma
cohorts were to small, the prognostic value for overall
survival was only performed in patients with squamous
cell carcinoma. Within this group, high expression of
integrin alpha5 and beta1 were associated with shorter
overall survival (Figure 4C).
Discussion
In order to select patients with a high risk of recurrence,
mRNA expression of multiple integrins by qPCR in
patients with resectable NSCLC was determined. To our
knowledge, this is the first study that assessed the expres-
sion of such a large panel of integrins simultaneously in
NSCLC patients. Only recently, Guo et al. performed
extensive integrin expression profiling in different lung
cancer cell lines[16]. Unfortunately, they did not address
integrin expression in tumor samples from NSCLC
patients. Nevertheless, they also identified integrin beta1
as the most abundantly expressed integrin while integrin
alpha4 was hardly detectable. This is in agreement with
our observations. On the other hand, all the cell lines
expressed integrin beta3 which was only detected in a
subset of our patients. The observed differences are most
likely related to the different cellular compositions and
environmental conditions in tumor tissues compared to
cultured tumor cell lines. Despite these differences, the
overall expression signatures were largely comparable
which is in agreement with earlier findings[17].
An interesting observation in the current study was
that increased expression of integrin alpha5 and integrin
beta1 predicts shorter overall survival and shorter disease
free survival of NSCLC patients. An association between
increased integrin alpha5 or beta1 expression and poor
patient outcome in NSCLC has been reported previ-
ously[8,11,18]. For example, Okamura et al. found that
increased integrin beta1 expression was a prognostic fac-
tor for poor overall survival in NSCLC patients[18].
Adachi et al. reported a significant worse 5-year survival
of node-negative NSCLC patients with high integrin
alpha5 expression. It was suggested that these patients
might have had undetected micro-metastases at time of
surgery or that they were more prone to metastasis[8].
Interestingly, Han et al. found that increased expression
of integrin alpha5 as well as integrin beta1 was associated
with lymph node metastasis in NSCLC patients[11]. We
Table 2: Primers targeting human integrins.
Target Forward primer (5' - 3') Reverse primer (5' - 3')
ITGα1 GGTTCCTACTTTGGCAGTATT AACCTTGTCTGATTGAGAGCA
ITGα2 GGAACGGGACTTTCGCAT GGTACTTCGGCTTTCTCATCA
ITGα3 AAGGGACCTTCAGGTGCA TGTAGCCGGTGATTTACCAT
ITGα4 GCTTCTCAGATCTGCTCGTG GTCACTTCCAACGAGGTTTG
ITGα5 TGCAGTGTGAGGCTGTGTACA GTGGCCACCTGACGCTCT
ITGα6 TTGAATATACTGCTAACCCCG TCGAAACTGAACTCTTGAGGATAG
ITGα7 CTGTTTCAGCTACATTGCAGTC GCCTGGTGCTTGGGTTCT
ITGα11 GGAGGAAGACTTGCGTCG CACAGGTTCCCCAGTAGATG
ITGαV AATCTTCCAATTGAGGATATCAC AAAACAGCCAGTAGCAACAAT
ITGβ1 GAAGGGTTGCCCTCCAGA GCTTGAGCTTCTCTGCTGTT
ITGβ3 CCGTGACGAGATTGAGTCA AGGATGGACTTTCCACTAGAA
ITGβ4 AGACGAGATGTTCAGGGACC GGTCTCCTCTGTGATTTGGAA
ITGβ5 GGAGCCAGAGTGTGGAAACA GAAACTTTGCAAACTCCCTC
ITGβ6 TCAGCGTGACTGTGAATATCC GTGACATTTGGAGCTGTTCAC
ITGβ8 AATTTGGTAGTGGAAGCCTATC GTCACGTTTCTGCATCCTTC
bACT GCTGTGCTACGTCGCCCTG GGAGGAGCTGGAAGCAGCC
cycloA CTCGAATAAGTTTGACTTGTGTTT CTAGGCATGGGAGGGAACA
b2MG TCCATCCGACATTGAAGTTG CGGCAGGCATACTCATCTT
HPRT1 AGAATGTCTTGATTGTGGAAGA ACCTTGACCATCTTTGGATTA
ITG = integrin, bACT = beta-actin, cycloA = cyclophilin A, b2MG = beta-2-microglobulin, HPRT = hypoxanthine-guanine 
phosphoribosyltransferase 1.Dingemans et al. Molecular Cancer 2010, 9:152
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could not find an association between the expression of
both integrins and lymph node metastasis. On the other
hand, we did observe that elevated expression of both
integrin alpha5 and integrin beta1 were prognostic fac-
tors for recurrence. All these data clearly show that both integrins are associated with a more aggressive pheno-
type in NSCLC, although the underlying mechanisms
remains to be elucidated. Possibly, elevated expression of
integrin alpha5beta1 increases the invasive potential of
lung tumor cells as shown by Takenaka et al. using the
human lung adenocarcinoma cell line PC9[19]. They
found that a highly metastatic variant of PC9 cells had
increased integrin alpha5beta1 expression and that the
metastatic potential could be reduced more than half by
treatment with an anti-beta1 antibody[19].
Apart from integrin alpha5 and beta1, it was also
observed that increased integrin beta3 expression was as
prognostic factor for overall and disease free survival.
However, integrin beta3 expression was only detected in
approximately one-third of the patients. Integrin beta3
has been shown to be exclusively expressed by the
endothelium of large vessels of normal lung tissue and
not in other tissue types of the normal lung[20]. Thus, the
absence of integrin beta3 may reflect a down-regulation
of this integrin or indicate an impaired vascularization of
a subset of tumors. Furthermore, integrin beta3 is often
found to associate with integrin alphaV in activated
endothelial cells during tumor angiogenesis. So, the ele-
vated integrin beta3 expression in patients with worse
prognosis might indicate increased angiogenesis activity.
Table 3: Characteristics of human integrin primer pairs in qPCR.
Integrin fragment length
(bp)
upper limit
(Ct)
slope
Alpha1 129 26.1 -3.38
Alpha2 154 31.2 -3.04
Alpha3 129 29.0 -3.38
Alpha4 131 36.4 -3.41
Alpha5 88 32.0 -3.23
Alpha6 113 30.5 -3.26
Alpha7 150 31.9 -3.43
Alpha11 123 34.0 -3.36
AlphaV 140 33.9 -3.31
Beta1 107 34.3 -3.23
Beta3 132 30.1 -3.30
Beta4 115 29.8 -3.12
Beta5 143 34.4 -3.39
Beta6 155 32.6 -3.33
Beta8 146 33.6 -3.50
ITG = integrin, bp = base pairs, Ct = Cycle threshold.
Figure 1 Integrin expression profile in NSCLC. A) Agarose gel elec-
trophoresis of the specific integrin fragments. M = 100 bp DNA marker. 
B) Representative dilution curves of 4 integrins showing a broad linear 
range of detection. Ct = Cycle threshold. C) Box plot of the overall in-
tegrin expression profile in NSCLC tissues.
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Table 4: Integrin expression and overall survival
Integrin Median OS (95% CI) in months
Low 
expression*
High 
expression
P
Alpha1 39.3 (0.0-97.4) 23.2 (0.0-46.8) Ns
Alpha2 31.9 (0.0-81.1) 18.4 (0.0-46.4) Ns
Alpha3 61.8 (21.1-102.5) 16.2 (12.2-20.2) 0.0
12
Alpha4 17.5 (0.0-50.5) 30.6 (10.1-51.2) Ns
Alpha5 44.4 (12.1-76.6) 14.7 (9.0-20.4) 0.0
06
Alpha6 31.9 (15.0-48.8) 36.1 (0.0-73.6) Ns
Alpha7 31.9 (0.0-63.8) 23.2 (0.0-52.2) Ns
Alpha11 31.9 (10.0-53.8) 32.8 (0.0-71.5) Ns
AlphaV 23.2 (0.0-56.1) 30.6 (8.7-52.5) Ns
Beta1 61.8 (0.0-129.3) 16.1 (13.2-19.0) 0.0
02
Beta3 61.8 (22.8-100.8) 11.5 (5.4-17.6) 0.0
13
Beta4 36.1 (20.6-51.5) 16.3 (14.1-18.5) Ns
Beta5 24.0 (3.5-44.6) 23.2 (0.0-50.8) Ns
Beta6 32.8 (4.5-61.1) 31.9 (0.0-64.5) Ns
Beta8 23.2 (3.0-43.4) 36.1 (1.2-71.0) Ns
*Low = below median, High = above medianDingemans et al. Molecular Cancer 2010, 9:152
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However, we did not find correlation between the expres-
sion of integrin alphaV and beta3 nor did integrin alphaV
expression associate with patient survival, lymph node
metastasis or recurrence. In fact, we observed relative
high expression levels of integrin alphaV which is contra-
diction with Smythe et al. who found that loss of integrin
alphaV is associated with a high risk for recurrence[12].
This discrepancy could be explained by the fact that the
latter study assessed protein expression while we deter-
mined mRNA expression levels. Studies to determine the
exact relation between integrin expression and the angio-
genic activity are ongoing.
Another interesting observation was that the different
subtypes of NSCLC have distinct integrin expression pro-
files. We observed higher expression of integrin alpha2
and beta4 specifically in squamous cell carcinoma which
is in agreement with a previous study by Koukoulis et al.
[21]. Furthermore, using an immunohistochemical
approach they were unable to detect integrin alpha4 and
Figure 2 Integrin expression profile and overall survival in 
NSCLC. Kaplan Meier plot of overall survival (OS) of patients with de-
tectable or undetectable integrin beta3 expression and of patients 
with low (below median) or high (above median) expression of the in-
dicated integrins.
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Table 5: Integrin expression and disease free survival
Integrin Median DFS (95% CI) in months
Low 
expression*
High 
expression
P
Alpha1 14.8 (0.0-64.2) 18.4 (8.3-28.5) Ns
Alpha2 20.8 (0.0-46.5) 18.4 (9.1-27.7) Ns
Alpha3 32.8 (0.0-73.3) 13.0 (8.5-17.4) Ns
Alpha4 13.8 (0.0-29.4) 18.6 (2.6-34.6) Ns
Alpha5 32.8 (5.7-59.9) 10.0 (8.4-11.6) 0.018
Alpha6 20.8 (10.1-31.5) 26.4 (2.2-50.6) Ns
Alpha7 18.6 (1.0-36.5) 20.8 (0.0-42.0) Ns
Alpha11 20.8 (3.4-38.2) 26.4 (0.0-58.5) Ns
AlphaV 14.8 (0.0-37.1) 18.4 (8.6-28.2) Ns
Beta1 61.8 (8.6-115.0) 12.4 (8.2-16.7) 0.012
Beta3 32.8 (0.0-79.4) 9.9 (2.8-17.1) 0.022
Beta4 20.9 (7.4-34.4) 13.0 (4.3-21.7) Ns
Beta5 14.8 (2.0-27.7) 20.8 (0.0-46.1) Ns
Beta6 26.4 (12.0-40.8) 14.8 (2.6-27.0) Ns
Beta8 10.7 (0.0-25.0) 26.4 (4.2-48.6) Ns
*Low = below median, High = above median
Figure 3 Integrin expression and disease free survival in NSCLC. Kaplan Meier plots of disease free survival (DFS) of patients with detectable or 
undetectable integrin beta3 expression and of patients with low (below median) or high (above median) expression of the indicated integrins.
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integrin beta3 protein expression which also corroborates
with the low mRNA levels detected in this study. On the
other hand, they could not detect integrin alpha4 or
alpha5 in any of the subtypes while the latter was identi-
fied as a prognostic factor in the current study . This is
most likely related to the experimental approach since
another study that analyzed integrin mRNA levels also
reported alpa4 and alpha5 expression[16]. In fact, the dif-
ferences in expression that we observed between
squamous and adenocarcinomas were largely in agree-
ment with the differences found when adenocarcinoma
cell line A549 was compared to squamous cell line Calu-1
in that same study[16]. Recently, Boelens et al. reported
on increased expression of integrin alpha3 in adenocarci-
noma compared to squamous cell carcinoma which is in
accordance with our results[10]. They also found elevated
integrin beta4 expression in squamous cell carcinoma as
compared to adenocarcinoma[10], similar as in our study.
Altogether, these studies indicate that integrin expression
profiles in adenocarcinoma and large cell carcinoma pro-
files are most alike and most different from squamous cell
carcinoma. The latter is the most common histological
type, it is central in location and most often late in devel-
opment of distant metastases. Interestingly, adenocarci-
noma is characterized by the early development of
metastases[22]. Since integrins are involved in many pro-
cesses associated with metastasis like loss of intracellular
adhesion within the primary tumor, tumor cell entry into
the lymphatic or blood vessels, and adherence of the
tumor cells the endothelium at distant sites[23], the
observed differences in integrin expression between both
subtypes might underlie the different metastatic poten-
tial. Furthermore, while this study focused on NSCLC,
integrins are of course implicated in tumor progression
and metastasis of many epithelial derived tumors[24-26].
For future studies it might be worthwhile to compare
integrin expression profiles in different epithelial tumors
to identify common themes in epithelial tumor progres-
sion.
In summary, this is the first study that correlates exten-
sive integrin mRNA expression profiling to the prognosis
of early stage NSCLC patients. Our findings identified
integrin alpha5, beta1, and beta3 as prognostic markers
for overall survival and disease free survival. In addition
Figure 4 Integrin expression profile and survival in subtypes of NSCLC. A) Bar graph showing the subtype specific integrin expression. B) Scatter 
plot showing the correlation in integrin expression between the different subtypes of NSCLC. C) Kaplan Meier plots of overall survival of patients with 
low (below median) or high (above median) expression of the indicated integrins in squamous carcinoma.
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we found distinct integrin expression profiles that can
differentiate between adenocarcinoma and squamous cell
carcinoma of the lung. These findings indicate that
changes in integrin expression in NSCLC play an impor-
tant role in the development and behavior of NSCLC
which influence the survival of the patient. Determining
the integrin expression profile might serve as a tool in
predicting the prognosis of individual patient and selec-
tion of patients who have a high risk of recurrence and
will benefit from adjuvant treatment.
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